It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
The following technology appraisals have been endorsed during 2021/22. Information on technology appraisals endorsed in previous years can be found on the homepage.
TA821 - Avalglucosidase alfa for treating Pompe disease
TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
'Note this guidance updates and replaces NICE Technology Appraisal TA711, which was endorsed by the DoH in July 2021'
TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
TA813 - Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
TA819 - Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
TA812 - Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer
TA810 - Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
TA809 - Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
TA808 - Fenfluramine for treating seizures associated with Dravet syndrome
TA807 - Roxadustat for treating symptomatic anaemia in chronic kidney disease
TA805 - Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
TA804 - Teduglutide for treating short bowel syndrome
TA802 - Cemiplimab for treating advanced cutaneous squamous cell carcinoma
‘Note this guidance updates and replaces NICE Technology Appraisal TA592, which was endorsed by the DoH in September 2019’
TA801 - Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
TA798 - Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
‘Note this guidance updates and replaces NICE Technology Appraisal TA578, which was endorsed by the DoH in May 2019’
TA796 - Venetoclax for treating chronic lymphocytic leukaemia
‘Note this guidance updates and replaces NICE Technology Appraisal TA487, which was endorsed by the DoH in February 2019’
TA795 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia
‘Note this guidance updates and replaces NICE Technology Appraisal TA491, which was endorsed by the DoH in February 2019’
TA794 - Diroximel fumarate for treating relapsing–remitting multiple sclerosis
TA792 - Filgotinib for treating moderately to severely active ulcerative colitis
TA791 - Romosozumab for treating severe osteoporosis
TA789 - Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
TA788 - Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
TA786 - Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA784 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
‘Note this guidance updates and replaces NICE Technology Appraisal TA528, which was endorsed by the DoH in January 2019’.
TA783 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
‘Note this guidance updates and replaces NICE Technology Appraisal TA510, which was endorsed by the DoH in February 2019’.
TA781 - Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
TA780 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma Note this guidance updates and replaces NICE Technology Appraisal TA581, which was endorsed by the DoH in June 2019
TA779 - Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency